Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial

IMPORTANCE: Additional therapies for amyotrophic lateral sclerosis (ALS) are urgently needed. Immune-mediated complement activation may be involved in ALS pathogenesis as evidenced by the upregulation of terminal components; thus, complement inhibition could potentially slow progression. OBJECTIVE:...

Descripción completa

Detalles Bibliográficos
Autores principales: Genge, Angela, van den Berg, Leonard H., Frick, Glen, Han, Steve, Abikoff, Cori, Simmons, Adam, Lin, Qun, Patra, Kaushik, Kupperman, Erik, Berry, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495927/
https://www.ncbi.nlm.nih.gov/pubmed/37695623
http://dx.doi.org/10.1001/jamaneurol.2023.2851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495927/
https://www.ncbi.nlm.nih.gov/pubmed/37695623
http://dx.doi.org/10.1001/jamaneurol.2023.2851

Ejemplares similares